E
Shares of Cyclacel Pharmaceuticals (CYCC) dropped as much as 75% on December 16, 2014 after the Data and Safety Monitoring Committee — DSMB — determined that the company’s drug known as sapacitabine would not reach its primary endpoint of survival in patients with AML — Acute Myeloid Leukemia. The Phase 3 trial known as SEAMLESS…